Case Report: Neoadjuvant and Adjuvant Crizotinib Targeted Therapy in Stage IIIA-N2 ALK-Positive Non-Small-Cell Lung Cancer

Case Report: Neoadjuvant and Adjuvant Crizotinib Targeted Therapy in Stage IIIA-N2 ALK-Positive Non-Small-Cell Lung Cancer

The treatment of anaplastic lymphoma kinase (ALK)-positive locally advanced non-small-cell lung cancer (NSCLC) is challenging because there is no randomized controlled trial has been reported. The value of neoadjuvant and adjuvant targeted therapy remains unclear. Herein, we show that systemic treat...

Full description

Bibliographic Details
Main Authors: Xiao-Hong Xie, Ze-Jiang Zhan, Yin-Yin Qin, Ju-Hong Jiang, Wei-Qiang Yin, Rong-Hui Zheng, Shi-Yue Li, Cheng-Zhi Zhou
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Oncology
Subjects:
locally advanced non-small-cell lung cancer
ALK inhibitor
neoadjuvant
adjuvant
targeted therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.655856/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.655856/full

Similar Items